NCT07127627Not yet recruiting
Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Characterization of Abdomino-pelvic Lesions in Cancer Patients by 18F-FDG PET/CT
Source: ClinicalTrials.gov · Last updated 17 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of the study is to identify and characterize lesions in the abdominopelvic region detected by 18fluorine- fluorodeoxyglucose (FDG) positron Emission Tomography combined Computed Tomography (PET/CT) scan, including determining their malignant or benign nature, and to determine the extent of disease to facilitate proper management
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 79 (estimated)
- First submitted
- 9 Aug 2025
- Start date
- Aug 2025
- Primary completion date
- Oct 2028
- Lead sponsor
- Assiut University
- Diseases
- Childhood cancers
- NCT number
- NCT07127627
What you commit to
- Study type: Observational
- Planned participants: 79
- From Aug 2025 to the primary completion date, Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients underwent recent abdominal or pelvic surgery.
Lab values
- patients with blood glucose level ˃200 mg/dL
Other
- Pregnancy
Who the study is looking for
- Inclusion criteria: All of the patients were suspected of having malignancy (new, recurrent or metastatic) based on pathology or conventional radiological studies and were referred to nuclear medicine unit for 18F-FDG-PET-CT scan
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.